Ets1 as a marker of malignant potential in gastric carcinoma

Table 1 Ets1 expression in tumor and stromal cells

Factors	No.	Ets1 percentage1 (mean ± SD)	P value	Ets1 percentage2 (mean ± SD)	P value
Total patients	40	35.0 ± 21.1		44.6 ± 17.5
Gender
Male	30	38.0 ± 22.5	0.115	45.2 ± 17.3	0.704
Female	10	25.9 ± 13.1		42.7 ± 18.7
Age
> 50	32	35.9 ± 20.8	0.572	46.3 ± 17.7	0.206
< 50	8	31.1 ± 23.3		37.5 ± 15.7
Histological classification (WHO)
Ad	30	35.2 ± 19.9	0.269	43.0 ± 15.4	0.647
Srcc	6	43.3 ± 26.4		49.3 ± 15.2
Uc	4	21.1 ± 19.6		48.8 ± 34.7
Grade (WHO)
I	7	26.9 ± 26.7	0.366	37.3 ± 18.3	0.486
II	19	39.5 ± 19.7		45.7 ± 11.6
III	14	32.8 ± 19.8		46.6 ± 23.2
T (tumor)
T1, 2	15	17.2 ± 12.0	< 0.001	35.3 ± 17.7	0.008
T3, 4	25	45.6 ± 17.9		50.1 ± 15.1
N (lymph node)
N0	14	24.1 ± 17.4	0.014	32.4 ± 13.8	0.001
N1, 2, 3	26	40.8 ± 20.8		51.1 ± 15.8
M (metastasis)
M0	39	34.0 ± 20.5	< 0.001	44.1 ± 17.5	< 0.001
M1	1	71		61
Clinical stage
I, II	18	21.8 ± 15.2	< 0.001	36.2 ± 18.1	0.005
III, IV	22	45.7 ± 19.2		51.4 ± 13.9

¹ refers to Ets1 expression in tumor cells ² refers to Ets1 expression in stromal cells.

Table 2 Intensity of Ets1 staining in tumor cell and distribu-tion of patients

Compartment	No.	Weak (+)	Moderate (++)	Intense (≥ +++)	P value
Tumor cells	40	6 (15%)	24 (60%)	10 (25%)
T classification
T1, 2	15	2 (13.3%)	12 (80%)	1 (6.7%)	0.087
T3, 4	25	4 (16%)	12 (48%)	9 (36%)
LN metastasis
Negative	14	3 (21.4%)	9 (64.3%)	2 (14.3%)	0.438
Positive	26	3 (11.5%)	15 (57.7%)	8 (30.8%)
Distant metastasis
Negative	39	6 (15.4%)	24 (61.5%)	9 (23.1%)	0.214
Positive	1	0 (0%)	0 (0%)	1 (100%)
Clinical stage
Stage I, II	18	3 (16.7%)	13 (72.2%)	2 (11.1%)	0.183
Stage III, IV	22	3 (13.6%)	11 (50%)	8 (36.4%)

Table 3 Intensity of Ets1 staining in stromal cell and distri-bution of patients

Compartment	No.	Weak (+)	Moderate (++)	Intense (≥ +++)	P value
Stromal cells	40	3 (7.5%)	21 (52.5%)	16 (40%)
T classification
T1, 2	15	3 (20%)	7 (46.7%)	5 (33.3%)	0.066
T3, 4	25	0 (0%)	14 (56%)	11 (44%)
LN metastasis*
Negative	14	3 (21.4%)	6 (42.9%)	5 (35.7%)	0.048
Positive	26	0 (0%)	15 (57.7%)	11 (42.3%)
Distant metastasis
Negative	39	3 (7.7%)	21 (53.8%)	15 (38.5%)	0.463
Positive	1	0 (0%)	0 (0%)	1 (100%)
Clinical stage
Stage I, II	18	3 (16.7%)	8 (44.4%)	7 (38.9%)	0.129
Stage III, IV	22	0 (0%)	13 (59.1%)	9 (40.9%)